FreeTheAI

Healthcare Growth Stocks Fall as Rising Treasury Yields Dampen Market Risk Appetite

BearishMedium impact
PACB$1.73 −11.73%MRNA$218.01 −7.82%MYGN$3.98 −8.51%AZTA$34.09 −6.65%RGEN$175.42 −4.75%

Shares of several healthcare and biotechnology companies dropped sharply during afternoon trading as rising Treasury yields prompted a broader market shift away from high-risk growth equities. Pacific Biosciences of California, Inc. (NASDAQ:PACB), Moderna, Inc. (NASDAQ:MRNA), Myriad Genetics, Inc. (NASDAQ:MYGN), Azenta, Inc. (NASDAQ:AZTA), and Repligen Corporation (NASDAQ:RGEN) all experienced price declines.

Higher interest rates directly impact long-duration assets by increasing the discount rates applied to projected future earnings. This reduces the present value of expected cash flows, which is particularly challenging for clinical-stage healthcare and drug development firms that depend on distant profits and frequent debt financing to fund ongoing research and development. In response, capital moved out of high-multiple healthcare assets toward government bonds and large-cap stocks.

Investors will be watching how these capital-intensive companies manage borrowing costs and research budgets if interest rates remain elevated. For Pacific Biosciences of California, Inc. (NASDAQ:PACB), which has experienced 86 stock moves over 5% in the past year, market attention will focus on whether upcoming business milestones and genomics partnerships can stabilize valuation amid persistent macroeconomic pressure.

Key points

  • Rising Treasury yields led to a sell-off in capital-intensive growth and life sciences equities.
  • Higher interest rates elevate discount rates on future earnings, lowering present valuations for early-stage healthcare firms.
  • Pacific Biosciences of California, Inc. (NASDAQ:PACB) fell over 11% during the trading session.
  • Moderna, Inc. (NASDAQ:MRNA), Myriad Genetics, Inc. (NASDAQ:MYGN), Azenta, Inc. (NASDAQ:AZTA), and Repligen Corporation (NASDAQ:RGEN) also declined.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why did healthcare and biotechnology stocks fall?

Elevated Treasury yields increased discount rates applied to future corporate earnings, reducing valuations for capital-intensive healthcare companies relying on future cash flows and debt funding.

Which stocks were affected by the market sell-off?

Declining stocks included Pacific Biosciences of California, Inc. (NASDAQ:PACB), Moderna, Inc. (NASDAQ:MRNA), Myriad Genetics, Inc. (NASDAQ:MYGN), Azenta, Inc. (NASDAQ:AZTA), and Repligen Corporation (NASDAQ:RGEN).

How do rising interest rates impact clinical-stage drug companies?

Higher interest rates raise borrowing costs and debt-servicing expenses, making it more expensive for clinical-stage healthcare firms to access debt markets and fund research and development.